Equities research analysts predict that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will announce earnings per share (EPS) of ($0.10) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics posted earnings per share of ($0.09) during the same quarter last year, which suggests a negative year-over-year growth rate of 11.1%. The firm is expected to issue its next earnings results before the market opens on Tuesday, October 17th.

According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.38) per share for the current fiscal year. For the next year, analysts anticipate that the firm will report earnings of ($0.42) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04.

Several research firms recently issued reports on BCLI. Maxim Group set a $8.00 price objective on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 13th. ValuEngine cut shares of Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, July 14th.

A number of institutional investors have recently added to or reduced their stakes in BCLI. KCG Holdings Inc. increased its position in Brainstorm Cell Therapeutics by 4.6% during the first quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 1,820 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in Brainstorm Cell Therapeutics during the second quarter worth about $2,759,000. Finally, Vanguard Group Inc. boosted its stake in Brainstorm Cell Therapeutics by 2.8% during the second quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock worth $2,733,000 after buying an additional 17,657 shares during the period. Hedge funds and other institutional investors own 12.69% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (BCLI) to Post -$0.10 Earnings Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/05/zacks-brokerages-anticipate-brainstorm-cell-therapeutics-inc-bcli-to-post-0-10-earnings-per-share.html.

Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) opened at 4.09 on Thursday. Brainstorm Cell Therapeutics has a 52-week low of $2.06 and a 52-week high of $5.18. The company’s market cap is $76.43 million. The stock’s 50 day moving average price is $4.16 and its 200-day moving average price is $4.19.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.